Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Bevacizumab Biosimilar in Intermediate HCC
NCT04843943Phase 2Unknown
- Sponsor
- Fudan University
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Fudan University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04843943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843943.